TICKERNERD
Menu
MMSIMMSIHealthcare · Medical Instruments & Supplies

MMSI Stock Forecast: Merit Medical Systems, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$91
+0.29% on the day

The 11 Wall Street analysts covering Merit Medical Systems, Inc. hold a median 12-month price target of $100 — +10.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$5.4B
Ticker Nerd rank
90 / 100
Median analyst target
$100
Analysts covering
11
Total return, dividends reinvested
1W
+1.9%
1M
+27.8%
YTD
+3.0%
1Y
+6.5%
From 52W high
−2.6%
From 52W low
+50.5%
$60
$93
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MMSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Merit Medical Systems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
90 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
98
Volatility
95
Quality
86
Value
77
Growth
71
Issuance
60
Accruals
52
Momentum
48
Size
23

Revisions (98): Analysts have, on balance, been raising their forecasts.

Momentum (48): The shares have been drifting down relative to others.

Size (23): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MMSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MMSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100$110$120Oct 25Jan 26Apr 26Jul 26MMSIHigh $114Median $100Low $83

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
9 Buy2 Hold0 Sell
Low $83Median $100High $114

The green dot is the last close — the median target sits +10.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026B of A SecuritiesMaintainsNeutral$92 → $97
11 Aug 2026BTIGReiteratesBuy$105
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Canaccord GenuityMaintainsBuy$85 → $94
31 July 2026BTIGMaintainsBuy$100 → $105
31 July 2026BTIGMaintainsBuy—
31 July 2026JP MorganMaintainsOverweight—
31 July 2026JP MorganMaintainsOverweight$77 → $95
31 July 2026NeedhamMaintainsBuy$90 → $101
31 July 2026NeedhamMaintainsBuy—
31 July 2026Piper SandlerMaintainsOverweight$96 → $106
31 July 2026Piper SandlerMaintainsOverweight—
31 July 2026Wells FargoMaintainsEqual-Weight$74 → $83
31 July 2026Wells FargoMaintainsEqual-Weight—
1 May 2026Canaccord GenuityMaintainsBuy$90 → $85
1 May 2026Canaccord GenuityMaintainsBuy—
1 May 2026JP MorganMaintainsOverweight—
1 May 2026JP MorganMaintainsOverweight$95 → $77
1 May 2026NeedhamMaintainsBuy$101 → $90
1 May 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MMSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

MMSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.7%
Analysts raising
1
Analysts cutting
0
Fundamentals

Merit Medical Systems, Inc. (MMSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
37.3×

Cheaper than 21% of US stocks

Price / sales
3.4×

Cheaper than 38% of US stocks

Price / book
3.2×

Cheaper than 33% of US stocks

EV / EBITDA
17.1×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
9.5%

Higher than 51% of US stocks

Earnings growth (YoY)
19.1%

Higher than 58% of US stocks

Gross margin
51.4%

Higher than 64% of US stocks

Operating margin
14.5%

Higher than 72% of US stocks

Net margin
9.2%

Higher than 68% of US stocks

Returns & dividend
Return on equity
9.2%

Higher than 61% of US stocks

Return on assets
4.9%

Higher than 76% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MMSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MMSIMerit Medical Systems, Inc.$5.4B
90
MMEDMiniMed Group, Inc.$5.7B
2
STVNStevanato Group SpA$5.7B
64
TFXTeleflex, Inc.$6.1B
82
BLCOBausch + Lomb Corp.$6.1B
86
NVSTEnvista Holdings Corp.$4.7B
99
ICUIICU Medical, Inc.$4.5B
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Merit Medical Systems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MMSI news & analysis

Merit Medical Eyes Next Growth Plan as Margins, Portfolio Review Take Center Stage

MarketBeat · 15 Aug 2026neutral

Merit Medical CFO and Treasurer Raul Parra said the company is focused on completing the objectives of its current long-range plan while developing its next strategic framework. The comments were made during a Canaccord investor event.

Why it matters — MMSI watchers would care because the company's near-term focus on margins and portfolio review, along with plans for its next strategic framework, signals where leadership intends to direct the business.

Merit Medical Systems Eyes New Long-Range Plan as Growth, Margins Gain Momentum

MarketBeat · 15 Aug 2026positive

Merit Medical Systems is preparing its next long-range plan as it navigates a leadership transition, updates its reporting structure, and aims to build on recent revenue and margin momentum.

Why it matters — A MMSI watcher would care because the company's upcoming long-range plan and ongoing leadership and reporting changes could shape its strategic direction amid improving revenue and margins.

COO vs. MMSI: Which Stock Should Value Investors Buy Now?

Zacks Investment Research · 5 Aug 2026neutral

Zacks Investment Research compared The Cooper Companies (COO) and Merit Medical Systems (MMSI) as value-investment options within the Medical-Dental Supplies sector.

Why it matters — MMSI watchers would care because the article evaluates Merit Medical's value-investment appeal relative to a key sector peer.

Merit Medical to Participate in Upcoming Investors Conferences in August

GlobeNewsWire · 5 Aug 2026neutral

Merit Medical Systems announced that its management will participate in upcoming investor conferences in August.

Why it matters — Investor conference participation gives MMSI watchers an opportunity to hear management's strategic messaging and potentially gauge market sentiment.

FAQ

Frequently asked questions about MMSI stock

What is the MMSI stock price forecast for 2026-2027?

The 11 Wall Street analysts covering Merit Medical Systems, Inc. have a median 12-month price target of $100, with estimates ranging from $83 to $114. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MMSI stock a buy right now?

Of the 11 analysts covering Merit Medical Systems, Inc., 9 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Merit Medical Systems, Inc. 90 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MMSI?

As at 15 Aug 2026, Merit Medical Systems, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (98 of 100).

Will MMSI stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +10.2% from the last close, and Ticker Nerd's factor model ranks Merit Medical Systems, Inc. 90 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MMSI stock forecast for 2030?

No analyst covering Merit Medical Systems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MMSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $83 to $114 over the next 12 months.

How has MMSI stock performed over the past year?

Merit Medical Systems, Inc. returned +6.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Merit Medical Systems, Inc. do?

Merit Medical Systems, Inc. is a medical device company that designs, develops, manufactures, and markets specialized disposable products for interventional and diagnostic procedures worldwide.

What is the latest news on MMSI?

The most recent item we track (MarketBeat, 15 Aug 2026): "Merit Medical Eyes Next Growth Plan as Margins, Portfolio Review Take Center Stage". Merit Medical CFO and Treasurer Raul Parra said the company is focused on completing the objectives of its current long-range plan while developing its next strategic framework. The comments were made during a Canaccord investor event.

Company

About Merit Medical Systems, Inc.

Merit Medical Systems, Inc. is a medical device company that designs, develops, manufactures, and markets specialized disposable products for interventional and diagnostic procedures worldwide. It operates through two primary segments: Cardiovascular and Endoscopy. The Cardiovascular segment provides cardiology and radiology devices for diagnosing and treating coronary arterial disease, peripheral vascular disease, and other non-vascular conditions, including embolotherapeutic products, cardiac rhythm management tools, electrophysiology devices, critical care monitors, breast cancer localization systems, biopsy instruments, interventional oncology solutions, and spine devices. The Endoscopy segment offers gastroenterology and pulmonology products such as stents and balloon dilators for palliative treatment of esophageal, tracheobronchial, and biliary strictures caused by malignant tumors. Within these segments, Merit Medical Systems delivers peripheral intervention tools like drainage catheters and microcatheters, cardiac intervention items including introducer sheaths and guide wires, custom procedural solutions, original equipment manufacturer components, and endoscopy devices. The company sells directly to hospitals and physicians in the United States and through distributors internationally, maintaining a global presence across North America, Europe, the Middle East, Africa, Asia, and Latin America. Founded in 1987 and headquartered in South Jordan, Utah, Merit Medical Systems supports healthcare professionals in vascular access, diagnostics, treatments, and patient monitoring with its portfolio of over 1,700 patented products.

CEO Ms. Martha Goldberg Aronson · 7,500 employees · United States · https://www.merit.com